Q4 2025 Raia Drogasil S/A Earnings Call (English, Portuguese) Transcript
Key Points
- Raia Drogasil SA (RADLY) reported a strong fourth quarter with a 19.8% year-on-year growth in gross revenue, reaching BRL47.6 billion.
- The company achieved a record-breaking Net Promoter Score (NPS) of 91, indicating high customer satisfaction.
- Digital revenue grew by over 50% for the third consecutive quarter, with retail penetration reaching 29.3%.
- Raia Drogasil SA (RADLY) opened 330 new stores with an impressive internal rate of return (IRR) of over 25%.
- The company gained 170 basis points in market share over 12 months, a record-breaking achievement across all regions.
- The sale of 4Bio was driven by a shift in market dynamics, with increased price pressure from hospitals and carriers, making the business less viable for Raia Drogasil SA (RADLY).
- The gross margin faced a slight decline due to the pressure from GLP-1 drugs, which have a smaller margin.
- Financial expenses increased due to higher interest rates and debt levels, impacting net profit.
- The company anticipates continued pressure on working capital due to the need for higher inventory levels, particularly for GLP-1 drugs.
- Despite strong digital growth, there is a need for ongoing investment in pricing and promotions to maintain competitiveness in the market.
Hello, everyone. Thank you for standing by, and welcome to RD Saúde's fourth quarter 2025 earnings conference call. This presentation can be found on RD Saúde's Investor Relations website at ri.rdsaude.com.br, where the replay for this conference will also be made available later. (Operator instructions)
Before proceeding, I'd like to mention that forward-looking statements are being made under the Safe Harbor of the Securities Litigation Reform Act of 1996. Forward-looking statements are based on the beliefs and assumptions of RD Saúde's management and on information currently available to the company.
Forward-looking statements are not guarantees of performance. They involve risks, uncertainties, and assumptions as they relate to future events and therefore, depend on circumstances that may or may not occur. Our investors should understand that general economic conditions, industry conditions, and other operating factors could also affect the future results of RD Saúde and could cause results to differ materially from those expressed in such forward-looking statements.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
